日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

基于模型指导的利格利珠单抗治疗慢性自发性荨麻疹患者的药物开发

Bienczak, Andrzej; Gautier, Aurelie; Hua, Eva; Ji, Yan; Scosyrev, Emil; Smeets, Serge; Severin, Thomas; Drollmann, Anton; Patekar, Manmath; Savelieva, Marina

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System

对健康志愿者和慢性自发性荨麻疹患者进行利格利珠单抗的药代动力学、药效学和耐受性综合评估,以优化其皮下给药系统。

Ji, Yan; Calonder, Claudio; Kirsilä, Tiina; Burciu, Alis; Tisu, Matjaz; Joubert, Yolandi; Laurent, Nathalie; Hua, Eva; Patekar, Manmath; Drollmann, Anton; Woessner, Ralph

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

茚达特罗/格隆溴铵对慢性阻塞性肺疾病患者通气和灌注的影响:一项随机试验

Singh, Dave; Wild, Jim M; Saralaya, Dinesh; Lawson, Rod; Marshall, Helen; Goldin, Jonathan; Brown, Matthew S; Kostikas, Konstantinos; Belmore, Kristin; Fogel, Robert; Patalano, Francesco; Drollmann, Anton; Machineni, Surendra; Jones, Ieuan; Yates, Denise; Tillmann, Hanns-Christian

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

每日一次服用NVA237可从首次给药起改善慢性阻塞性肺病患者的运动耐量:GLOW3试验

Beeh, Kai M; Singh, Dave; Di Scala, Lilla; Drollmann, Anton

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

茚达特罗在健康受试者中的心脏安全性:一项随机、多剂量、安慰剂和阳性对照、平行组QT间期全面研究

Khindri, Sanjeev; Sabo, Ronald; Harris, Stuart; Woessner, Ralph; Jennings, Simon; Drollmann, Anton F